# Puma Biotechnology Inc (PBYI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.55, market value $493 million.

## Valuation
- **P/E (trailing): 18.7×** (5-yr avg 8.1×, 3-yr avg 8.1×). Puma Biotechnology Inc trades at 18.7× trailing earnings, well above its own five-year average of 8.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 27.3×, higher than trailing, so analysts expect earnings to fall.
- **Price / sales: 2.1×**. Each dollar of revenue is priced at 2.1×.
- **Price / book: 3.5×**. The shares trade at 3.5× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.9×**. Enterprise value is 11.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 8.3%** (5-yr avg 12.2%). Free cash flow equals 8.3% of the market value, below its five-year average of 12.2%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 5.3%**. The inverse of the P/E: 5.3% of the price is earned each year.

## Profitability
- **Operating margin: 13.2%**. 13.2% of revenue is left after running the business.
- **Net margin: 13.6%**. 13.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 23.9%**. 23.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 19.5%**. Return on all capital, debt included, is 19.5%: comfortably above what that capital costs.
- **Return on assets: 12.4%**. Each dollar of assets produces 12.4% of profit.

## Growth
- **Revenue growth (1 yr): -0.9%** (3-yr 0.0%/yr, 5-yr 0.3%/yr). Revenue fell 0.9% over the last year, against 0.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -1.6%**. Earnings per share fell 1.6%, roughly in step with revenue.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Puma Biotechnology Inc holds more cash than debt.
- **Altman Z-score: 5.91**. A Z-score of 5.91 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Puma Biotechnology Inc does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 86.9%** (YTD 60.5%, 3-mo 35.8%). The shares are up 86.9% over twelve months including dividends.
- **From 52-week high: -2.0%** (122.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 0.56** (volatility 60%). Beta of 0.56 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PBYI · Page: https://foliofundamentals.com/stocks/pbyi

Not investment advice.